Potential predictive factors for development of treatment-emergent suicidal ideation in the fluoxetine placebo-controlled major depressive disorder database

被引：0
|
作者：
Beasley, Charles [1 ]
Disch, Damon [1 ]
Prabhakar, Venkat [1 ]
Desaiah, Durisala [1 ]
Tamura, Roy [1 ]
Perlis, Roy [1 ]
机构：
[1] Eli Lilly & Co, Lilly Res Lab, Indianapolis, IN 46285 USA
来源：
NEUROPSYCHOPHARMACOLOGY | 2006年 / 31卷
关键词：
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
引用
收藏
页码：S100 / S101
页数：2
相关论文
共 50 条
  • [1] Placebo-controlled trial of agomelatine in the treatment of major depressive disorder
    Kennedy, SH
    Emsley, R
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2006, 16 (02) : 93 - 100
  • [2] A placebo-controlled trial of escitalopram and sertraline in the treatment of major depressive disorder
    Alexopoulos, GS
    Gordon, J
    Zhang, DZ
    NEUROPSYCHOPHARMACOLOGY, 2004, 29 : S87 - S87
  • [3] Randomized, placebo-controlled trial of Fluoxetine for-acute treatment of minor depressive disorder
    Judd, LL
    Rapaport, MH
    Yonkers, KA
    Rush, AJ
    Frank, E
    Thase, ME
    Kupfer, DJ
    Plewes, JM
    Schettler, PJ
    Tollefson, G
    AMERICAN JOURNAL OF PSYCHIATRY, 2004, 161 (10): : 1864 - 1871
  • [4] Potential Biomarkers for Diagnosing Major Depressive Disorder Patients with Suicidal Ideation
    Bai, Shunjie
    Fang, Liang
    Xie, Jing
    Bai, Huili
    Wang, Wei
    Chen, Jian-jun
    JOURNAL OF INFLAMMATION RESEARCH, 2021, 14 : 495 - 503
  • [5] Treatment patterns of patients with major depressive disorder and suicidal ideation or attempt
    Kern, David M.
    Cepeda, M. Soledad
    Wiegand, Frank
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 68 - 68
  • [6] A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder
    Garakani, Amir
    Martinez, Jose M.
    Marcus, Sue
    Weaver, James
    Rickels, Karl
    Fava, Maurizio
    Hirschowitz, Jack
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2008, 23 (05) : 269 - 275
  • [7] Randomized, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder
    DeMartinis, N.
    Yeung, P. P.
    Entsuah, R.
    Manley, A. L.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 : S233 - S234
  • [8] Factors Predictive of Treatment-Emergent Adverse Events of Prucalopride: An Integrated Analysis of Four Randomized Double-Blind, Placebo-Controlled Trials
    Leelakusolvong, Somchai
    Ke, MeiYun
    Zou, Duowu
    Choi, Suck Chei
    Tack, Jan
    Quigley, Eamonn M. M.
    Liu, Andy
    Kim, JinYong
    GUT AND LIVER, 2015, 9 (02) : 208 - 213
  • [9] Metabolic features of treatment-refractory major depressive disorder with suicidal ideation
    Pan, Lisa A.
    Naviaux, Jane C.
    Wang, Lin
    Li, Kefeng
    Monk, Jonathan M.
    Lingampelly, Sai Sachin
    Segreti, Anna Maria
    Bloom, Kaitlyn
    Vockley, Jerry
    Tarnopolsky, Mark A.
    Finegold, David N.
    Peters, David G.
    Naviaux, Robert K.
    TRANSLATIONAL PSYCHIATRY, 2023, 13 (01)
  • [10] Metabolic features of treatment-refractory major depressive disorder with suicidal ideation
    Lisa A. Pan
    Jane C. Naviaux
    Lin Wang
    Kefeng Li
    Jonathan M. Monk
    Sai Sachin Lingampelly
    Anna Maria Segreti
    Kaitlyn Bloom
    Jerry Vockley
    Mark A. Tarnopolsky
    David N. Finegold
    David G. Peters
    Robert K. Naviaux
    Translational Psychiatry, 13
12345